Thomas Cotter, MD
Gastroenterology · Dallas, TXNPI 1023426335
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,800 of the $26,107 with a category attached, or 98.8%. Madrigal Pharmaceuticals accounts for 99.0% of it on its own, with 2 other manufacturers making up the rest. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4 payments — averaging $6526.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$26K
- Intercept Pharmaceuticals, Inc.$144
- Novo Nordisk$120
Across 28 payments — averaging $5766.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$161K
What the payments were for
- Consulting fees$25,80099%
- Food & beverage$3071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 2 | $25,843 |
| Intercept Pharmaceuticals, Inc. | 1 | $144 |
| Novo Nordisk | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$144
How this compares
$26,107 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 19 | $58,392 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $26,002 |
| Tenofovir Disoproxil Fumarate | 17 | $3,417 |
| Entecavir | 13 | $1,700 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 16 | $1,090 |
| Ursodiol | 14 | $489 |
| Lactulose | 15 | $270 |
| Spironolactone | 20 | $247 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 14 | $200 |
| Furosemide | 26 | $121 |
| Carvedilol | 40 | $119 |
| Pantoprazole Sodium | 15 | $80 |
| Ondansetron Hcl | 16 | $64 |
| Tamsulosin Hcl | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Dallas
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Parvez MantryDallas$958K
- Jay HortonDallas$326K
- Jacqueline O LearyDallas$157K
- Sami ArslanlarDallas$142K
- Amit DesaiDallas$71K
- Byron CryerDallas$68K
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.